OSBORNE DAVID W 4
4 · Arcutis Biotherapeutics, Inc. · Filed Mar 2, 2023
Insider Transaction Report
Form 4
OSBORNE DAVID W
Chief Technical Officer
Transactions
- Sale
Common Stock
2023-03-02$16.52/sh−15$248→ 254,644 total - Sale
Common Stock
2023-02-28$16.17/sh−792$12,804→ 255,857 total - Sale
Common Stock
2023-03-02$15.82/sh−1,198$18,951→ 254,659 total
Footnotes (3)
- [F1]The sale was effected pursuant to the Reporting Person's Rule 10b5-1 trading plan to satisfy tax withholding obligations in connection with the vesting of restricted stock units.
- [F2]The transaction was executed in multiple trades in prices ranging from $15.990 to $16.320, inclusive. The price reported in Column 4 above reflects the weighted average sale price. The Reporting Person hereby undertakes to provide to the Securities and Exchange Commission staff, the Issuer, or a security holder of the Issuer, upon request, full information regarding the number of shares sold at each respective price within the range set forth in this footnote.
- [F3]The transaction was executed in multiple trades in prices ranging from $15.470 to $16.460, inclusive. The price reported in Column 4 above reflects the weighted average sale price. The Reporting Person hereby undertakes to provide to the Securities and Exchange Commission staff, the Issuer, or a security holder of the Issuer, upon request, full information regarding the number of shares sold at each respective price within the range set forth in this footnote.